Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Jones Trading on Capricor Therapeutics (CAPR): 'this is the first time we have seen the magnitude of difference in primary outcome'
July 27, 2026 2:36 PM EDTJones Trading analyst Catherine Novack reiterated a Buy rating and $51.00 price target on Capricor Therapeutics (NASDAQ: CAPR).
The analyst comments "What's New: FDA released briefing documents ahead of the July 29 AdCom meeting for deramiocel (LINK). The reviewers concluded that deramiocel studies did NOT provide substantial evidence of effectiveness... More
H.C. Wainwright on Capricor Therapeutics (CAPR): 'Cage Match Expected at Wednesday's AdCom as Drama with FDA Continues'
July 27, 2026 12:31 PM EDTH.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $60.00 price target on Capricor Therapeutics (NASDAQ: CAPR).
The analyst comments "The timing of the SAP revisions raises questions regarding functional unblinding. The FDA acknowledges that SAP Versions 2.0 and 3.0 were finalized before formal database lock and unblinding, but notes that the randomized, double-blind treatment period had already ended. The FDA also... More
